Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Ammann

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Annals of Surgical Oncology|August 28, 2025
ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Environmental Science & Technology|April 23, 2026
Ubiquity of Aviation Ultrafine Particles and Lubrication Oil Compounds Near Zurich AirportSarah Tinorua, Benjamin T Brem, Zachary C J Decker, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
JHEP Reports : Innovation in Hepatology|March 24, 2025
Soluble TREM2 reflects liver fibrosis status and predicts postoperative liver dysfunction after liver surgeryJonas Santol, Dragana Rajcic, Gregor Ortmayr, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 3, 2025
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBIYawen Dong, Lindsey A Gregory, Vanja Podrascanin, et al.
Annals of Surgical Oncology|December 19, 2025
The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Annals of Surgical Oncology|August 28, 2025
ASO Visual Abstract: Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel in Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Environmental Science & Technology|April 23, 2026
Ubiquity of Aviation Ultrafine Particles and Lubrication Oil Compounds Near Zurich AirportSarah Tinorua, Benjamin T Brem, Zachary C J Decker, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
JHEP Reports : Innovation in Hepatology|March 24, 2025
Soluble TREM2 reflects liver fibrosis status and predicts postoperative liver dysfunction after liver surgeryJonas Santol, Dragana Rajcic, Gregor Ortmayr, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 3, 2025
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBIYawen Dong, Lindsey A Gregory, Vanja Podrascanin, et al.
Annals of Surgical Oncology|December 19, 2025
The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center AnalysisVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pageof 12